Free Trial

Amedisys, Inc. (NASDAQ:AMED) is Alpine Associates Management Inc.'s 4th Largest Position

Amedisys logo with Medical background

Alpine Associates Management Inc. raised its stake in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 0.9% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 1,280,897 shares of the health services provider's stock after buying an additional 11,000 shares during the period. Amedisys comprises about 5.6% of Alpine Associates Management Inc.'s portfolio, making the stock its 4th largest holding. Alpine Associates Management Inc. owned 3.92% of Amedisys worth $117,586,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. lifted its stake in shares of Amedisys by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 312,032 shares of the health services provider's stock valued at $29,662,000 after purchasing an additional 8,422 shares during the period. BNP Paribas Financial Markets boosted its stake in shares of Amedisys by 74.0% during the 4th quarter. BNP Paribas Financial Markets now owns 5,692 shares of the health services provider's stock worth $541,000 after acquiring an additional 2,421 shares in the last quarter. Norges Bank purchased a new stake in shares of Amedisys during the 4th quarter worth about $34,032,000. Hilltop Holdings Inc. acquired a new stake in shares of Amedisys during the 4th quarter valued at about $2,001,000. Finally, Allianz Asset Management GmbH increased its stake in shares of Amedisys by 146.0% in the 4th quarter. Allianz Asset Management GmbH now owns 39,855 shares of the health services provider's stock valued at $3,789,000 after purchasing an additional 23,655 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.


Amedisys Price Performance

Shares of Amedisys stock traded down $0.03 during mid-day trading on Monday, reaching $96.88. 273,140 shares of the stock traded hands, compared to its average volume of 325,839. The business has a 50-day moving average of $97.75 and a 200 day moving average of $94.70. Amedisys, Inc. has a fifty-two week low of $89.55 and a fifty-two week high of $98.95. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $3.17 billion, a PE ratio of -151.06, a PEG ratio of 1.89 and a beta of 0.78.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.10. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. The firm had revenue of $591.19 million for the quarter, compared to the consensus estimate of $579.34 million. On average, analysts predict that Amedisys, Inc. will post 4.66 EPS for the current year.

Analyst Upgrades and Downgrades

AMED has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research report on Thursday, July 25th. Deutsche Bank Aktiengesellschaft lowered Amedisys from a "buy" rating to a "hold" rating and set a $101.00 target price on the stock. in a research report on Monday, July 29th. Finally, William Blair lowered shares of Amedisys from an "outperform" rating to a "market perform" rating in a report on Monday, July 1st. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $100.67.

Check Out Our Latest Stock Analysis on AMED

Amedisys Company Profile

(Free Report)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

See Also

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

→ War on Elon Escalates… (From Porter & Company) (Ad)

Should you invest $1,000 in Amedisys right now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Is Palantir Heading for a $50 Price Target?
Rate Cuts Fuel Volatility: How Long Could it Last?
SMCI Stock: Is a Rebound Coming?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines